We are delighted to be working with the University of Southampton to raise funds to help find a cure for Non-Hodgkin's Lymphoma.
The University of Southampton has established a UK-wide consortium – Precision Medicine for Aggressive Lymphoma (PMAL) - to support new treatments for lymphoma based upon the precise molecular characteristics of the cancer itself. PMAL is led by Professor Peter Johnson, Professor of Medical Oncology at the University of Southampton, former Chair of the NCRI Lymphoma Clinical Studies Group, Cancer Research UK Lead Clinician and current Medical Director of the Francis Crick Institute. He has extensive experience in the delivery of clinical and translational research in malignant lymphoma.
A new trial, led by the Southampton Clinical Trials Unit at our new Centre for Cancer Immunology, aims to harness the effect of antibodies which block the 'off' signals of the immune system, which we hope may improve the results of treatment for people whose lymphoma has come back after initially successful chemotherapy. This is a difficult situation, and one where our current approaches to treatment often fail. The trial brings together the expertise in the Southampton Centre for Cancer Immunology with our PMAL consortium to test whether combining chemotherapy and this novel antibody treatment can increase the likelihood of success.
We already have support for the costs of the antibodies themselves and the infrastructure of the clinical trial, but we lack the funds to carry out the cutting-edge analysis of the effects on the immune system by this treatment, and relate them to the molecular features of the cancer. This is where we need your help. We need to make sure that we learn all we can from the patients who agree to take part, to find out what precise features may predict who is most likely to benefit, and how we can tell this early on in their treatment.
Professor Tim Elliott - Professor of Experimental Medicine at The University Of Southampton.